Helmy is a serial entrepreneur and pioneer in the biotech industry. After receiving his PhD, MS and BS degrees in electrical engineering from Stanford University, he joined the Stanford Genome Technology Center (SGTC) in 2006 to work on low-cost DNA sequencing technologies. At SGTC, he developed the first semiconductor sequencing platform and first base-calling algorithm for next-gen sequencing. In 2007, he co-founded Avantome to commercialize a low-cost, high-performance next-gen sequencing platform to seed the democratization of next-gen sequencing. As its founding CEO, he led Avantome through two rounds of financing and through acquisition by Illumina in 2008. At Illumina, Helmy was Sr Director of Advanced Technology Research, where he developed novel chemistries, hardware and informatics for genetic analysis systems.
AmirAli is a serial entrepreneur in the sample preparation and clinical research fields. Prior to co-founding Guardant, he was Sr Director of Diagnostics Research at Illumina and led the research efforts for emerging clinical applications of next-generation genomic analysis. During that time, he developed different sample preparation technologies suitable for clinical applications. Before Illumina, he founded Auriphex Biosciences, which focused on purification and genetic analysis of circulating tumor cells for cancer management. The technology was acquired by Illumina in 2009. Prior to his industrial career, he led the Technology Development group at Stanford Genome Technology Center. AmirAli received his PhD in electrical engineering and MSc in management science from Stanford University.
Michael joined Guardant Health in 2012 as Chief Financial Officer. He is responsible for overseeing all finance and legal at the Company. Prior to joining Guardant, Michael worked as CFO at Voyage Medical, a medical device company, for over 4 years. Prior to Voyage, Michael was VP of Finance at Microchip Biotechnologies, Inc., where he led the team that raised both Series A and Series B financings for the company. Earlier in his career, Michael was a corporate attorney at Venture Law Group and acted as in-house associate counsel for Novell where he focused on intellectual property and employment issues. Prior to receiving a J.D. degree from the J. Reuben Clark Law School at Brigham Young University, Michael worked for KPMG as a tax advisor and CPA.
Guardant Health is committed to positively and significantly impacting patient health through technology breakthroughs that pointedly address long-standing unmet needs in oncology. Guardant is backed by Sequoia Capital, led by a seasoned management team comprising thought leaders and successful serial entrepreneurs in next-generation sequencing and rare-cell diagnostics and is closely advised by an oncologist-led medical steering committee from leading cancer centers across North America and abroad.
© 2014 GUARDANT HEALTH, INC. ALL RIGHTS RESERVED.
Legal / Privacy